Oncoustics AI

High-Level Overview

Oncoustics AI is a Toronto-based medtech startup developing advanced AI solutions that analyze raw ultrasound signals to enable low-cost, non-invasive surveillance, diagnostics, and treatment monitoring for diseases with high unmet needs, particularly liver disease.[1][2][3][5] The company builds the OnX liver assessment solution, a virtual biopsy tool that differentiates healthy from diseased tissues using novel acoustic biomarkers, targeting a $60B+ global liver diagnostics market where millions are eligible for screening amid rising epidemics like MASLD and MASH.[1][2][5] It serves clinicians (hepatologists, gastroenterologists, primary care), biopharma partners, and patients by solving the lack of affordable point-of-care tools for early detection and staging, with deployments in 100+ clinics, introductions to hundreds of KOLs, and >4M pieces of proprietary RF signal data—the world's largest dataset.[1][2] Growth includes $11.2M raised ($8M seed/pre-seed from Saltagen Capital, Creative Ventures, Sony Innovation Fund; $3.2M non-dilutive), FDA submissions underway, partnerships with DIGITAL for AI consortia, and expansions to prostate, kidney, thyroid, and women's health.[1][2][3]

Origin Story

Founded in Toronto, Oncoustics emerged from the need to address growing liver disease epidemics without inexpensive point-of-care diagnostics, leveraging AI to mine raw ultrasound RF signals for tissue characterization.[1][3] Beth Rogozinski, the CEO, leads the company, emphasizing its unique technology for rapid assessments that enable personalized medicine in a single visit.[3] The idea gained traction through prospectively collected datasets exceeding 4M data points, starting with liver focus due to hepatologists' demand for primary care tools to triage high-need patients.[1] Pivotal moments include June 2024's INOVAIT Focus Fund award for point-of-care liver diagnostics, January 2025's DIGITAL co-investment to build a Canadian AI healthcare consortium, and introductions to 100+ clinics plus biopharma/OEM partners.[1][2][3]

Core Differentiators

• Proprietary AI on Raw Signals: Applies machine learning to unprocessed ultrasound RF data for acoustic biomarkers, enabling virtual biopsies without invasive procedures—unique as the largest >4M dataset spans liver, prostate, kidney, breast, and thyroid.[1][2]
• Point-of-Care Accessibility: Low-cost, non-invasive tools like OnX work on any ultrasound-imaged anatomy, speeding diagnostics, reducing costs, and supporting surgical guidance/drug development; deployed in 10+ clinics for data collection.[1][3]
• Clinical and Regulatory Momentum: FDA submissions for OnX liver solution, introduced to 70-100+ clinics and hundreds of KOLs; partnerships with pharma/CROs for DILI, MASLD/MASH, and cancers.[1][2]
• Ecosystem Building: Seeks pharma, clinical, ML experts, reimbursement pros; backed by top VCs and non-dilutive grants, with educational campaigns and consortia like DIGITAL.[2][3]

Role in the Broader Tech Landscape

Oncoustics rides the AI-in-healthcare wave, specifically point-of-care ultrasound AI amid a liver disease crisis—1B+ affected globally, 3x U.S. liver cancer rise since 1980, and unmet needs in early screening for MASLD/MASH.[1][5] Timing aligns with AI commercialization pushes (e.g., Canada's DIGITAL cluster) and regulatory tailwinds like FDA ultrasound AI clearances, democratizing access in under-digitized healthcare.[2][3] Market forces favor it: $60-65B diagnostics opportunity, biopharma demand for monitoring tools, and ultrasound ubiquity vs. costly biopsies/MRIs.[1][2] It influences the ecosystem by fostering AI consortia, enabling pharma trials, and shifting hepatology toward primary care triage, positioning Canada as an AI medtech leader.[3]

Quick Take & Future Outlook

Oncoustics is poised to capture liver diagnostics dominance with OnX FDA approvals, follow-on products for inflammation/cancer, and platform expansions to other organs via its unmatched dataset.[1][2] Trends like AI precision medicine, point-of-care proliferation, and MASH drug pipelines will accelerate growth, with pharma partnerships and reimbursements unlocking scale. Its influence may evolve into a multi-disease platform leader, bridging diagnostics and therapeutics in a $60B+ market—transforming Oncoustics from virtual biopsy pioneer to healthcare access game-changer.[1][3]